摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-cyclopropylpyrazine-2-carboxylic acid | 1211537-40-4

中文名称
——
中文别名
——
英文名称
5-cyclopropylpyrazine-2-carboxylic acid
英文别名
——
5-cyclopropylpyrazine-2-carboxylic acid化学式
CAS
1211537-40-4
化学式
C8H8N2O2
mdl
——
分子量
164.164
InChiKey
ZTVADTYTPQWTHB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    63.1
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    5-cyclopropylpyrazine-2-carboxylic acid草酰氯N,N-二甲基甲酰胺 作用下, 以 二氯甲烷 为溶剂, 反应 0.08h, 生成
    参考文献:
    名称:
    [EN] MODULATORS OF THE INTEGRATED STRESS PATHWAY
    [FR] MODULATEURS DE LA VOIE DE RÉPONSE INTÉGRÉE AU STRESS
    摘要:
    本文提供了用于调节综合应激反应(ISR)并治疗相关疾病、疾病和症状的化合物、组合物和方法。
    公开号:
    WO2019090076A1
  • 作为产物:
    描述:
    methyl 5-cyclopropylpyrazine-2-carboxylate 在 lithium hydroxide monohydrate 、 作用下, 以 四氢呋喃甲醇 为溶剂, 以3 g的产率得到5-cyclopropylpyrazine-2-carboxylic acid
    参考文献:
    名称:
    [EN] FUSED HETEROCYCLIC DERIVATIVES
    [FR] DÉRIVÉS HÉTÉROCYCLIQUES FUSIONNÉS
    摘要:
    该申请描述了融合杂环衍生物化合物,包括这些化合物的制药组合物,制备这些化合物的化学过程以及它们在治疗与HBV感染相关的疾病中的用途。
    公开号:
    WO2022253259A1
点击查看最新优质反应信息

文献信息

  • Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use
    申请人:Merck Sharp & Dohme Corp.
    公开号:US20150307465A1
    公开(公告)日:2015-10-29
    In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, -L 2 -, and -L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.
    本发明提供了多种形式的亚氨基噻二唑二氧化物化合物,包括公式(I)的化合物: 包括它们的立体异构体,以及所述立体异构体的药用可接受盐,其中R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、-L2-和-L3-都是独立选择且按本文定义。发明的新型亚氨基噻二唑二氧化物化合物出人意料地被发现具有预期的特性,使其作为BACE抑制剂以及/或用于治疗和预防与β-淀粉样蛋白(“Aβ”)生成相关的各种病理学具有优势。还公开了包含一个或多个此类化合物(单独使用和与一个或多个其他活性成分组合使用)的药物组合物,以及它们的制备方法和用于治疗与淀粉样β(Aβ)蛋白相关的病理学,包括阿尔茨海默病的方法。
  • [EN] PYRAZINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRAZINE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2014072257A1
    公开(公告)日:2014-05-15
    The present invention relates to compounds of formula (I), wherein R1R2 are hydrogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cycloalkyl, OCH2-cycloalkyl or heterocycloalkyl which is optionally substituted by halogen, with the proviso that one of R1 and R2 is hydrogen, or R1 and R2 form together with the carbon atom to which they are attach a phenyl ring, which may be optionally substituted by lower alkyl; R3/R4 are hydrogen, halogen or cyano; with the proviso that one of R3 and R4 is hydrogen; or to a pharmaceutically suitable acid addition salt thereof, to all racemic mixtures, all their corresponding enantiomers and/or optical isomers, which may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
    本发明涉及式(I)的化合物,其中R1R2为氢、较低的烷基、较低的烷氧基、受卤素取代的较低烷基、受卤素取代的较低烷氧基、环烷基、OCH2-环烷基或杂环烷基,该杂环烷基可以选择性地受卤素取代,但R1和R2中的一个为氢,或者R1和R2与它们连接的碳原子一起形成苯环,该苯环可以选择性地受较低烷基取代;R3/R4为氢、卤素或氰基;但R3和R4中的一个为氢;或其药学上适宜的酸盐,所有的外消旋混合物,它们对应的对映体和/或光学异构体,可用于治疗抑郁症、焦虑症、躁郁症、注意缺陷多动障碍(ADHD)、与压力有关的疾病、精神疾病、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用、代谢紊乱、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍,以及心血管疾病。
  • [EN] IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE<br/>[FR] COMPOSÉS DE DIOXYDE D'IMINOTHIADIAZINE COMME INHIBITEURS DE BACE, COMPOSITIONS ET LEUR UTILISATION
    申请人:SCHERING CORP
    公开号:WO2011044181A1
    公开(公告)日:2011-04-14
    In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): (I) and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R1, R2, R3, R4, R5, R9, ring A, ring B, m, n, p, -L1-,L2-, and L3- is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (Aβ) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers disease, are also disclosed.
    在其多种实施方式中,本发明提供了某些亚氨基噻二嗪二氧化物化合物,包括化合物式(I)的化合物和其立体异构体,以及所述化合物立体异构体的药学上可接受的盐,其中每个R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、L2-和L3-都是独立选择并在此定义。该发明的新型亚氨基噻二嗪二氧化物化合物出人意料地表现出具有优势的BACE抑制剂特性和/或用于治疗和预防与β-淀粉样蛋白(Aβ)产生相关的各种病理的特性。还公开了包括一种或多种这样的化合物(单独和与一种或多种其他活性剂的组合)的制药组合物,并揭示了在治疗与淀粉样β(Aβ)蛋白相关的病理,包括阿尔茨海默病中使用它们的方法。
  • IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE
    申请人:Scott Jack D.
    公开号:US20120183563A1
    公开(公告)日:2012-07-19
    In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): (I) and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -,L 2 -, and L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (Aβ) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers disease, are also disclosed.
    在其多种实施方式中,本发明提供了某些亚硫酰二氮杂环化合物,包括化合物式(I):(I)及其立体异构体和所述化合物立体异构体的药学上可接受的盐,其中R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、L2-和L3-各自独立选择并如所定义。本发明的新型亚硫酰二氮杂环化合物出人意料地表现出预期的性质,使它们作为BACE抑制剂和/或用于治疗和预防与β-淀粉样蛋白(Aβ)产生相关的各种病理学具有优势。还公开了包括一种或多种这样的化合物(单独和与一种或多种其他活性剂的组合)的制药组合物,以及用于治疗与淀粉样β(Aβ)蛋白相关的病理学,包括阿尔茨海默病的方法。
  • IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE
    申请人:Scott Jack D.
    公开号:US20140296221A1
    公开(公告)日:2014-10-02
    In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, -L 2 -, and -L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.
    在其多种实施方式中,本发明提供了某些亚氨基噻二嗪二氧化物化合物,包括化合物公式(I)的化合物:以及其立体异构体和该化合物立体异构体的药学上可接受的盐,其中每个R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、-L2-和-L3-独立选择并在此定义。本发明的新型亚氨基噻二嗪二氧化物化合物出乎意料地表现出有利于作为BACE抑制剂和/或用于治疗和预防与β-淀粉样蛋白(“Aβ”)产生相关的各种病理的性质。还公开了包括一个或多个此类化合物(单独和与一个或多个其他活性剂的组合)的制药组合物,以及用于治疗与淀粉样β(Aβ)蛋白相关的病理,包括阿尔茨海默病的制备和使用方法。
查看更多